Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jean B. Regard, Hiroshi Kataoka, David A. Cano, Eric Camerer, Liya Yin, Yao-Wu Zheng, Thomas S. Scanlan, Matthias Hebrok, Shaun R. Coughlin
Published in Volume 117, Issue 12
J Clin Invest. 2007; 117(12):4034–4043 doi:10.1172/JCI32994
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5
Administration of T1AM causes Adra2a- and Gi-dependent hyperglycemia and hypoinsulinemia.

(A) Blood glucose levels following administration of T1AM (50 mg/kg, i.p.) or vehicle. T1AM induced hyperglycemia in wild-type (n = 6–7; *P < 0.01, **P < 0.001) but not in RIP-PTX mice. (B) Blood insulin levels 2 hours following vehicle or T1AM injection as in A relative to preinjection levels. Note the 60% decrease in insulin levels after T1AM in wild-type (n = 6; #P < 0.005) but not RIP-PTX mice. (C and D) The effects of T1AM on GSIS in isolated islets from mice (C) and humans (D). T1AM (10 μM) was capable of inhibiting GSIS in a PTX-sensitive manner in both species (PTX pretreatment 50 ng/ml for 16 hours). Data are presented as relative insulin secreted/total insulin (mean ± SEM; n = 3–4; ##P < 0.05). (E) Chemical similarity of T1AM and catecholamines. (F) Competition of T1AM and epinephrine for [3H]RX821002 binding to membranes from Cos cells transfected with an expression vector for human or mouse Adra2a. Binding of [3H]RX821002 was Adra2a transfection dependent. (G) Blood glucose levels 1 hour following T1AM administration to control mice and Adra2a-null mice. Note that control mice became hyperglycemic following T1AM administration (n = 9; ΧP = 0.001), but Adra2a-null mice became hypoglycemic (n = 11–12; ΧΧP = 0.003).